A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.
about
A lesson for cancer research: placental microarray gene analysis in preeclampsiaBiomedical applications of functionalized hollow mesoporous silica nanoparticles: focusing on molecular imagingAnti-angiogenesis in prostate cancer: knocked down but not outSurface engineering of graphene-based nanomaterials for biomedical applicationsSelecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane ProteinsTargeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem CellsAttenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse modelsEngineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacyModulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer.Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors?Tumor vasculature targeting: a generally applicable approach for functionalized nanomaterials.Src-mediated post-translational regulation of endoglin stability and function is critical for angiogenesisTheranostic unimolecular micelles based on brush-shaped amphiphilic block copolymers for tumor-targeted drug delivery and positron emission tomography imagingNew radiotracers for imaging of vascular targets in angiogenesis-related diseases.In vivo tumor vasculature targeted PET/NIRF imaging with TRC105(Fab)-conjugated, dual-labeled mesoporous silica nanoparticles.Activin receptor inhibitors--dalantercept.Immuno-PET imaging of tumor endothelial marker 8 (TEM8)Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies.Positron emission tomography imaging of angiogenesis in a murine hindlimb ischemia model with 64Cu-labeled TRC105Angiogenesis and lymphangiogenesis in the spectrum of leprosy and its reactional forms.Bio-functionalized dense-silica nanoparticles for MR/NIRF imaging of CD146 in gastric cancerReducing endoglin activity limits calcineurin and TRPC-6 expression and improves survival in a mouse model of right ventricular pressure overload.Red fluorescent zinc oxide nanoparticle: a novel platform for cancer targeting.Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105)Gene Electrotransfer of Plasmid with Tissue Specific Promoter Encoding shRNA against Endoglin Exerts Antitumor Efficacy against Murine TS/A Tumors by Vascular Targeted Effects.In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine.An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.High Yield Production and Radiochemical Isolation of Isotopically Pure Arsenic-72 and Novel Radioarsenic Labeling Strategies for the Development of Theranostic Radiopharmaceuticals.Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancerPositron emission tomography imaging of tumor angiogenesis with a (61/64)Cu-labeled F(ab')(2) antibody fragmentTumor vasculature targeting and imaging in living mice with reduced graphene oxide.PET imaging of CD105/endoglin expression with a ⁶¹/⁶⁴Cu-labeled Fab antibody fragmentCardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.Imaging tumor angiogenesis in breast cancer experimental lung metastasis with positron emission tomography, near-infrared fluorescence, and bioluminescenceImage-guided and tumor-targeted drug delivery with radiolabeled unimolecular micelles.Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles.Positron emission tomography imaging of CD105 expression in a rat myocardial infarction model with (64)Cu-NOTA-TRC105.Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls.
P2860
Q26827543-F705F3E2-4786-465D-92B1-61A1BF225094Q26827998-E6E1C636-F125-4274-A0DF-7FCBA38C73EAQ26851183-C3D06D6D-B508-48F8-86CB-2728061E407BQ26853158-CFEE3547-E8EA-40BD-A500-15258372D7DDQ28077999-E364B44F-D5B1-465D-997F-7F9137445F1CQ28078154-BFEE86DC-DB50-4824-B6F3-E3ADBAC09371Q33633839-FC4AE58D-C0AE-4EEE-BD00-19505ABDC758Q33640207-C6F07D7A-8C00-4875-9BD0-6A192A8C2AEDQ33687218-B656E9DE-4082-4D4A-8CBA-9E0E35704081Q33913556-AAC5A0D7-4155-4522-B68C-CBECA96D9535Q33957962-8BBE583E-8327-4EC8-91A9-1CC49A359F5BQ34019838-BA003FFC-8E80-4BDC-8C03-61B2564107B3Q34170622-6AC287BB-F368-45AF-962A-350A02CE5876Q34178035-03D1EF48-609D-4DD6-9ED8-B9AF1B2CD35EQ34216877-789D4F35-8CED-41AB-9577-B3A3FC5D7EE2Q34446399-9DC3F2B3-AD1D-4190-8B73-C2818A7A07DCQ34464168-2676ED38-BFDC-4A71-93CF-ED98D7719881Q34473434-3A3D03FD-1279-47DA-B134-34E9665D01F8Q34540047-C70F7EE4-2BC0-4328-A02E-E60705E68786Q34759659-C631A841-E4C5-4A99-8BE4-32AD3819E46AQ34990214-2D0742D4-1E7A-4BD8-B498-39300E1A853EQ35024238-2B9E6F0B-0094-4862-8007-A243BFB3E76EQ35026300-7448C22F-9E19-497A-9F96-8D0390082642Q35079462-403ECF93-2E24-4B82-BF6C-C2D87589150DQ35158941-8C02B89F-B6BD-4F59-A1A4-6836635262AEQ35536671-AE263D3C-59BB-42B1-A983-D08291A315E1Q35554806-599C2E4E-6F59-4015-B364-4173429197F4Q36061812-DC273568-8BAF-485A-B2FC-048AF1B3A170Q36483855-C9880048-84E8-4543-9C41-A0E19761D713Q36510958-9EE329F9-7E9A-4710-87C6-AB202A32B18AQ36586091-7F61DC45-12ED-4C40-B778-A9878792C46FQ36604948-B7E45000-BDC8-4867-A350-15A5125D5D1EQ36763112-74B545D7-5600-4ACE-B6E4-5FF52FFDDD83Q36891574-2F658F94-BAD8-41D5-9CB7-E2D88024E4B4Q36996613-5FE4F013-50BA-4CDE-9448-A4CBC9962A74Q37202881-236625BD-4580-4BBC-BA66-9DA0CB2B3968Q37236103-450372CA-25AD-43A4-BE7D-EFF0353CEE59Q37327759-C3752152-FF16-4D92-9774-EAB1933BAC3EQ37402601-5BF605FA-E5A2-471D-A108-FA3EA33A61DBQ37479646-77FF4464-73E6-4F78-91EC-1789CC975B32
P2860
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A phase I first-in-human study ...... patients with advanced cancer.
@ast
A phase I first-in-human study ...... patients with advanced cancer.
@en
type
label
A phase I first-in-human study ...... patients with advanced cancer.
@ast
A phase I first-in-human study ...... patients with advanced cancer.
@en
prefLabel
A phase I first-in-human study ...... patients with advanced cancer.
@ast
A phase I first-in-human study ...... patients with advanced cancer.
@en
P2093
P2860
P1476
A phase I first-in-human study ...... patients with advanced cancer.
@en
P2093
Ben K Seon
Bonne J Adams
Bryan R Leigh
Charles P Theuer
David S Mendelson
Delia Alvarez
Herbert I Hurwitz
Jonathan Goldman
Lee S Rosen
Michael K Wong
P2860
P304
P356
10.1158/1078-0432.CCR-12-0098
P407
P577
2012-07-05T00:00:00Z